Neuphoria Therapeutics Inc. (NEUP) stock

NEUPNasdaqPharmaceutical PreparationsFiscal year ends June 30

Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 18, 2026Score 5/30

$2.55−0.03 (-1.16%)

Close on Nov 13, 2026Market cap $76.66KP/E –Yield –

Neuphoria Therapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Neuphoria Therapeutics's price to book ratio was 0.0× on Nov 11, 2026, against 0.0× a year earlier. Over the last 4 years it ranged from 0.0× to 0.0×, with a median of 0.0×.

Price to Book Ratio at the end of each year

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	0.0×	−0.0
2025	Dec 31, 2025	0.0×	+0.0
2024	Dec 31, 2024	0.0×	−0.0
2023	Dec 29, 2023	0.0×	−0.0
2022	Dec 30, 2022	0.0×	–

Where these numbers come from

Parsed from the XBRL in Neuphoria Therapeutics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-2160 reverse split on Feb 14, 2025
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is NEUP.

Compare: NEUP vs IGC · NEUP vs KRSA · NEUP vs DNTH · NEUP vs OVID · NEUP vs ATXI

Revenue growth-92.5% · median -46.7%

Operating margin-1401.1% · median -2843.5%

Net margin-1145.7% · median -1836.7%

Company	Revenue	Growth
OVID	$1.45M	-78.0%
NEUP	$1.17M	-92.5%
IGC	$1.12M	-15.4%
KRSA	–	–
DNTH	–	–
ATXI	–	–

Company

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: June 30
Employees: 7
Held by institutions: 36.8%
Auditor: Wolf & Company P.C.
SEC CIK: 1191070

Advertisement
300 × 250

See a number that looks wrong?

Neuphoria Therapeutics price to book ratio

Price to Book Ratio at the end of each year

More Neuphoria Therapeutics figures